[go: up one dir, main page]

JP2007238598A5 - - Google Patents

Download PDF

Info

Publication number
JP2007238598A5
JP2007238598A5 JP2006307035A JP2006307035A JP2007238598A5 JP 2007238598 A5 JP2007238598 A5 JP 2007238598A5 JP 2006307035 A JP2006307035 A JP 2006307035A JP 2006307035 A JP2006307035 A JP 2006307035A JP 2007238598 A5 JP2007238598 A5 JP 2007238598A5
Authority
JP
Japan
Prior art keywords
stroke
patient
composition
composition according
history
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006307035A
Other languages
Japanese (ja)
Other versions
JP5069448B2 (en
JP2007238598A (en
Filing date
Publication date
Application filed filed Critical
Priority to JP2006307035A priority Critical patent/JP5069448B2/en
Priority claimed from JP2006307035A external-priority patent/JP5069448B2/en
Publication of JP2007238598A publication Critical patent/JP2007238598A/en
Publication of JP2007238598A5 publication Critical patent/JP2007238598A5/ja
Application granted granted Critical
Publication of JP5069448B2 publication Critical patent/JP5069448B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (7)

イコサペント酸エチルエステルを有効成分として含有する、血清ＴＧ／ＨＤＬ−Ｃ比が３．７５以上の脳卒中既往患者の脳卒中再発予防用組成物。 A composition for preventing recurrence of stroke in a patient with a history of stroke having a serum TG / HDL-C ratio of 3.75 or more, comprising icosapentic acid ethyl ester as an active ingredient. ３年以上継続して投与するための請求項１に記載の組成物。The composition of claim 1 for continuous administration for 3 years or more. ４年以上継続して投与するための請求項１または２に記載の組成物。The composition according to claim 1 or 2 for continuous administration for 4 years or more. 前記脳卒中既往患者が、脳卒中発症後６ヶ月を経過した後の患者である請求項１ないし３のいずれかに記載の組成物。The composition according to any one of claims 1 to 3, wherein the patient with a history of stroke is a patient after 6 months have passed since the onset of stroke. 前記脳卒中既往患者が、高脂血症患者である請求項１ないし４のいずれかに記載の組成物。The composition according to any one of claims 1 to 4, wherein the past stroke patient is a hyperlipidemic patient. イコサペント酸エチルエステルとしての１日投与量が０．３〜６ｇである経口投与のための請求項１ないし５のいずれかに記載の組成物。6. The composition according to any one of claims 1 to 5, for oral administration, wherein the daily dose as icosapentic acid ethyl ester is 0.3 to 6 g. イコサペント酸エチルエステルを有効成分として含有する、３年以上継続して投与するための、脳卒中既往患者の脳卒中再発予防用組成物。A composition for preventing recurrence of stroke in a patient with a history of stroke, which is administered continuously for 3 years or more, containing icosapentate acid ethyl ester as an active ingredient.
JP2006307035A 2006-02-07 2006-11-13 Composition for preventing stroke recurrence Active JP5069448B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2006307035A JP5069448B2 (en) 2006-02-07 2006-11-13 Composition for preventing stroke recurrence

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006029954 2006-02-07
JP2006029954 2006-02-07
JP2006307035A JP5069448B2 (en) 2006-02-07 2006-11-13 Composition for preventing stroke recurrence

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006194043A Division JP4005104B2 (en) 2006-02-07 2006-07-14 Composition for preventing stroke recurrence

Publications (3)

Publication Number Publication Date
JP2007238598A JP2007238598A (en) 2007-09-20
JP2007238598A5 true JP2007238598A5 (en) 2009-08-20
JP5069448B2 JP5069448B2 (en) 2012-11-07

Family

ID=38584473

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006307035A Active JP5069448B2 (en) 2006-02-07 2006-11-13 Composition for preventing stroke recurrence

Country Status (1)

Country Link
JP (1) JP5069448B2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110236476A1 (en) 2008-09-02 2011-09-29 Amarin Corporation Plc. Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
WO2010127103A1 (en) 2009-04-29 2010-11-04 Amarin Pharma, Inc. Stable pharmaceutical composition and methods of using same
SG175390A1 (en) 2009-04-29 2011-12-29 Amarin Corp Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
SI2443246T1 (en) 2009-06-15 2018-05-31 Amarin Pharmaceuticals Ireland Limited Compounds and procedures for lowering triglycerides without increasing the levels of LDL-C in an individual who is simultaneously receiving statin therapy
EP2646013A4 (en) 2010-11-29 2014-03-26 Amarin Pharma Inc LOW-ERUCATION COMPOSITION AND METHODS FOR TREATING AND / OR PREVENTING CARDIOVASCULAR DISEASE IN A SUBJECT HAVING FISH ALLERGY / HYPERSENSITIVITY
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
WO2014005013A2 (en) 2012-06-29 2014-01-03 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
HUE067138T2 (en) 2018-09-24 2024-10-28 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of cardiovascular events in a subject
CN116350616A (en) 2019-11-12 2023-06-30 阿马里纳药物爱尔兰有限公司 Method for reducing the risk of cardiovascular events in subjects with atrial fibrillation and/or atrial flutter
US11986452B2 (en) 2021-04-21 2024-05-21 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022713B2 (en) * 2004-02-19 2006-04-04 Kowa Co., Ltd. Hyperlipemia therapeutic agent

Similar Documents

Publication Publication Date Title
JP2007238598A5 (en)
ATE510537T1 (en) PHARMACEUTICAL COMPOSITIONS OF ENTACAPONE, LEVODOPA AND CARBIDOPA WITH IMPROVED BIOAVAILABILITY
JP2012517449A5 (en)
JP2006504795A5 (en)
NZ807894A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
EA200700049A1 (en) PREPARATIVE FORMS OF ORAL MEDICINAL FORMS OF MEMANTINE WITH MODIFIED SURVIVAL
FI3782612T3 (en) Oral formulations of cytidine analogs and methods of use thereof
JP2007523049A5 (en)
IL191312A0 (en) Oral pharmaceutical dosage form comprising as active ingredients a proton pump inhibitor together with acetyl salicyclic acid
ME02662B (en) Low frequency glatiramer acetate therapy
UA110012C2 (en) MEDICINAL FORM FOR ORAL APPLICATION CONTAINING LICARBAZEPINE ACETATE
HRP20151202T1 (en) Oral formulation of metadoxine
WO2007012022A3 (en) Unit dose form with ibuprofen-famotidine admixture
HRP20170734T1 (en) Increased bioavailability of the drug in NALTREXON therapy
HRP20110497T4 (en) PROCEDURES FOR THE APPLICATION OF AMINOPYRIDINE COMPOSITIONS WITH EXTENDED RELEASE
MA28862B1 (en) PHARMACEUTICAL COMPOSITION IN THE FORM OF A GASTRIC RESISTANCE COMPRESSOR CONTAINING AN ACTIVE INGREDIENT
WO2008075320A3 (en) Antilipidemic pharmaceutical compositions and process for preparation thereof
MX2009004579A (en) A pharmaceutical composition having antipsychotic, antidepressant or antiepiieptic activity with reduced side effect.
JP2008266291A5 (en)
WO2007121545A8 (en) S-nitrosothiols containing compositions for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compositions
JP2009516719A5 (en)
ATE410152T1 (en) THERAPEUTIC SYSTEM WITH AMOXICILLIN AND CLAVULANIC ACID
JP2012097036A5 (en)
WO2006062933A3 (en) Stable compositions of fenofibrate with fatty acid esters
JP2006342148A5 (en)